View Older Stories View More Recent Stories

Jun 28, 2024 07:02AM Moderna (MRNA) Reports Positive EMA Opinion Recommending Marketing Authorization of mRESVIA
Jun 28, 2024 07:00AM EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Jun 13, 2024 07:02AM Moderna (MRNA) Reports Positive Phase 3 Efficacy Data for mRNA-1283
Jun 13, 2024 07:00AM Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Jun 10, 2024 06:30AM Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Jun 10, 2024 05:31AM Moderna (MRNA) Reports Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Jun 7, 2024 10:31AM Moderna (MRNA) Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Jun 7, 2024 10:30AM Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Jun 6, 2024 07:00AM Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
May 31, 2024 02:00PM Moderna (MRNA) Announces FDA Approval for mRESVIA
May 31, 2024 11:00AM Moderna (MRNA) Receives U.S. FDA Approval for RSV Vaccine mRESVIA
May 31, 2024 10:58AM Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 10:58AM Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 10:58AM Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 22, 2024 07:00AM Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
May 13, 2024 07:00AM Moderna to Present at Upcoming Conferences in May/June 2024
May 10, 2024 07:07AM Moderna (MRNA) Issues Update on Investigational RSV Vaccine
May 10, 2024 07:00AM Moderna Announces Update on Investigational RSV Vaccine
May 8, 2024 08:30AM Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
May 2, 2024 06:30AM Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Apr 25, 2024 07:00AM Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
Apr 24, 2024 08:00AM Moderna and OpenAI Collaborate To Advance mRNA Medicine
Apr 22, 2024 07:04AM Moderna (MRNA) to Supply 12.5M COVID-19 Vaccines to Brazil
Apr 22, 2024 07:00AM Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
Apr 17, 2024 07:00AM Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Apr 8, 2024 08:00AM Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
Apr 3, 2024 11:06AM Moderna (MRNA) Announces Publication of Phase 1/2 Interim Data on mRNA-3927
Apr 3, 2024 11:00AM Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Mar 26, 2024 07:03AM Moderna (MRNA) Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Mar 26, 2024 07:00AM Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Feb 29, 2024 07:00AM Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Feb 28, 2024 07:00AM Moderna to Present at Upcoming Investor Conferences in March 2024
Feb 7, 2024 12:00AM Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Feb 1, 2024 07:00AM Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Jan 31, 2024 05:45PM Moderna Named to Fortune's List of World's Most Admired Companies
Jan 8, 2024 07:07AM Moderna (MRNA) FY23 Revenue Tops Estimates
Jan 8, 2024 07:00AM Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Jan 5, 2024 10:00AM Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
Dec 20, 2023 04:05PM Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 15, 2023 08:01AM Moderna (MRNA) Announces NEJM Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational RSV Vaccine
Dec 14, 2023 06:00PM Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vacc
Dec 12, 2023 08:04AM Moderna (MRNA) Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Dec 12, 2023 08:00AM Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Dec 11, 2023 07:00AM Merck (MRK), Moderna (MRNA) initiate INTerpath-002 Phase 3 trial of V940/KEYTRUDA combo in NSCLC
Dec 11, 2023 06:45AM Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected N
Dec 7, 2023 07:00AM Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Nov 1, 2023 10:30AM Flagship Pioneering Launches Pioneering Intelligence
Sep 11, 2023 07:00AM Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Aug 29, 2023 09:00AM Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
Jul 26, 2023 06:45AM Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Study Evaluating V940 in Combination with KEYTRUDA
View More Recent Stories View Older Stories